PT  - JOURNAL ARTICLE
AU  - González-Pérez, Antonio
AU  - Vizcaya, David
AU  - Sáez, María E
AU  - Lind, Marcus
AU  - Garcia Rodriguez, Luis A
TI  - Cardiovascular and Renal Outcomes among Patients with Type 2 Diabetes using SGLT2 Inhibitors added to Metformin: A Population-Based Cohort Study from the United Kingdom
AID  - 10.1101/2022.07.28.22278158
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.07.28.22278158
4099  - http://medrxiv.org/content/early/2022/07/31/2022.07.28.22278158.short
4100  - http://medrxiv.org/content/early/2022/07/31/2022.07.28.22278158.full
AB  - Introduction As large numbers of patients with type 2 diabetes receive treatment with a sodium-glucose co-transporter-2 inhibitor (SGLT2i), we investigated whether the cardio-renal preventative effects found in clinical trials are also seen in clinical practice where patient characteristics and adherence to treatment differs.Research design and methods Using UK primary care electronic health records, we followed two cohorts of patients with type 2 diabetes prescribed metformin: SGLT2is (N=12,978) and a matched comparator of patients not using a SGLT2i at the start of follow-up (N=44,286). Independent follow-ups were performed to identify the study outcomes – Cox regression to estimate adjusted hazard ratios (HRs) for the study outcomes: cardiovascular (CV) composite outcome (comprising non-fatal myocardial infarction [MI]/ischaemic stroke [IS] requiring hospitalisation and CV death), severe renal disease, and all-cause mortality.Results Mean follow-up was 2.3 years (SGLTi cohort) and 2.1 years (comparison cohort). Mean age was 60.4 years (SD ±10.2, SGLTi cohort) and 60.4 years (SD ± 10.0, comparison cohort). SGLT2i new users were associated with a reduced risk of the CV composite (HR 0.75, 95% CI: 0.61–0.93), severe renal disease (HR 0.55, 95% CI: 0.46– 0.67), and all-cause mortality (HR 0.56, 95% CI: 0.49–0.63), with risk reductions similar irrespective of baseline CKD. Reduced risks were seen for IS (HR 0.51, 95% CI: 0.36–0.74) but not MI (HR 0.98, 95% CI: 0.74–1.28). Results were consistent in sensitivity analyses.Conclusions In this population-based study, SGLT2is were associated with significant CV, renal and survival benefits among individuals with type 2 diabetes on metformin; the CV benefit was driven by a reduced risk of ischaemic stroke.What is already known on this topic?In randomized controlled trials (RCTs), sodium-glucose co-transporter-2 inhibitors (SGLT2is) and have shown good efficacy in reducing the risk of adverse cardiovascular (CV) and renal events in patients with type 2 diabetes.These benefits of SGLT2is have also been seen in observational studies, but have shown uncertainty around the evidence for benefits on myocardial infarction (MI).RCTs and observational studies differ in the characteristics of patients studied and in their adherence to treatment.What this study adds?In this matched retrospective cohort study among patients with type 2 diabetes using metformin, those who started an SGLT2i had significantly reduced risks of all-cause mortality (44% risk reduction), severe renal disease (50% risk reduction), a CV composite outcome (non-fatal MI/ischaemic stroke requiring hospitalisation/CV death; 25% risk reduction) and ischaemic stroke (49 risk reduction) compared with those who didn’t start a SGLT2i; however, the risk of non-fatal MI was not significantly different between groups.These findings indicate that the beneficial effects on CV disease seen in trials are driven by a reduced risk of ischaemic stroke.How this study might affect research, practice or policyThese results confirm that the benefits of SGLT2i in patients with type 2 diabetes observed in clinical trials are applicable to real-world settings, thereby supporting an increasing role of SGLT2i in diabetes care.Competing Interest StatementAG-P, MES and LAGR work for CEIFE, which has received research funding from Bayer AG. LAGR also declares honoraria for attendance at advisory board meetings for Bayer. DV is an employee of Bayer. ML has received research grants from Eli Lilly and Novonordisk and been a paid consultant or received honoraria from Astra Zeneca, Boehringer Ingelheim, Eli Lilly and Novonordisk.Funding StatementThe study was funded by Bayer AGAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Independent Scientific Research Committee for IQVIA Medical Research Data-UK (IMRD-UK) gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors